Biorg Leadership
Biorg's team combines scientific expertise with deep curiosity, passion for collaboration, and commitment to scientific innovations that benefit society
Timothy R. Wright
CEO
Mr. Timothy R. Wright serves as CEO of Biorg. He is the Co-Founder and Chairman of Isosceles Pharmaceuticals, a pre-clinical stage pharmaceutical company developing intravenous formulations of a synthetic cannabidiol for the treatment of post operative pain. Additionally, Tim is the Founder of the Drug Development Institute at The Ohio State Comprehensive Cancer Center (https://cancer.osu.edu/for-cancer-researchers/research/research-institutes-and-centers/drug-development-institute) and Co-Founder of The Oncology Research Information Exchange Network (www.Oriencancer.org). Tim served as President and CEO of Mimedx and M2 Gen, EVP of TEVA Mergers and Acquisitions and Innovation, President of Covidien Mallinkrodt, Chief Operating Officer of Elan, SVP of Cardinal Health and Dupont Merck Pharmaceuticals. Additionally, Tim is on the Board of Directors of Agenus Bio and Protogenics.
Goodwell Nzou, PhD
COO
Dr. Nzou serves as COO of Biorg and leads scientific strategy and technology development focused on advance human-relevant models for precision medicine and drug development. He has expertise in organoids, microphysiological systems, tissue engineering, and translational research. His work includes developing complex in vitro models, personalized cancer-drug-response platforms, and technologies that translate laboratory discoveries into clinically meaningful solutions.
Dr. Nzou earned his PhD in Molecular Medicine and Translational Sciences from Wake Forest University School of Medicine. He has led multidisciplinary collaborations across academia, biotechnology, and clinical research. At Biorg, he advances organoid-based technologies and scalable platforms designed to accelerate therapeutic development, improving, drug evaluation, and enable personalized approaches to patient care and precision medicine.